Standard BioTools Inc. filed a current report on Form 8-K on November 19, 2026, disclosing the results of a virtual special meeting at which stockholders voted to approve all seven proposals related to a pending merger with Treeline Biosciences, Inc.
Key Highlights
- Quorum reached: 281,744,412 votes, approximately 71.38% of total voting power, were present or represented by proxy at the Special Meeting held November 19, 2026.
- Share issuance approved: Stockholders approved the issuance of Common Stock in connection with the Merger, with 274,099,041 votes for and 7,571,806 against.
- Name change and reverse split approved: Stockholders approved amending the certificate of incorporation to rename the company "Treeline Biosciences, Inc." and to effect a reverse stock split at a ratio in the range of 1-for-20 to 1-for-40, with the final ratio to be mutually agreed upon by the company and Treeline Biosciences, Inc.
- Asset divestiture approved: The Element Mass Cytometry Divestiture proposal, which may constitute a sale of substantially all company assets under Section 271 of the Delaware General Corporation Law, was approved with 276,299,544 votes for and 5,336,020 against.
- Post-closing equity plans approved: Both the Post-Closing Equity Incentive Plan and the Post-Closing Employee Stock Purchase Plan were approved, each contingent on the closing of the Merger.
- Record date shares: At the October 16, 2026 record date, there were 394,711,296 shares of Common Stock issued, outstanding, and entitled to vote.
Standard BioTools Stockholder Vote Clears Path for Treeline Merger
According to the filing, Standard BioTools Inc. (NASDAQ:LAB) held a virtual special meeting of stockholders on November 19, 2026, at which all seven proposals presented in the company's definitive proxy statement/prospectus were approved. The proxy statement/prospectus was filed with the SEC on October 21, 2026 pursuant to Rule 424(b)(3) and formed part of a registration statement on Form S-4 (File No. 333-297560), which the SEC declared effective on October 21, 2026.
The company disclosed that the Charter Amendment Proposal, approved with 275,584,914 votes for and 6,123,396 against, would amend the company's Eighth Amended and Restated Certificate of Incorporation to effect a reverse stock split and change the corporate name to "Treeline Biosciences, Inc." The filing states the specific reverse split ratio within the 1-for-20 to 1-for-40 range is to be mutually agreed upon by Standard BioTools and Treeline Biosciences, Inc. The Post-Closing Equity Incentive Plan and Post-Closing ESPP, the filing notes, "will become effective at the effective time of the Merger" and are "each contingent on the closing of the Merger."
The Advisory Compensation Proposal, described as a nonbinding advisory vote on Transaction-Related Compensation, received 248,805,322 votes for and 15,966,136 against. The Adjournment Proposal was also approved with 255,788,813 votes for. The filing states there were no broker non-votes with respect to any of the proposals. The current report was signed by Alex Kim, Chief Financial Officer of Standard BioTools Inc.
What Was Disclosed
Standard BioTools Inc. reported that its stockholders approved all seven merger-related proposals at a November 19, 2026 special meeting, including share issuance, a corporate name change to Treeline Biosciences, a reverse stock split, an asset divestiture, and two post-closing equity compensation plans.




Please wait processing your request...